FiercePharmaOriginal article
{"a":[{"_":"IntraBio's Aqneursa scores expansion, now the first treatment for rare ataxia","$":{"href":"/pharma/intrabio-scores-aqneursa-expansion-now-first-treatment-globally-rare-ataxia","hreflang":"en"}}]}
RegulatoryapprovedAqneursaPositive
AI Analysis
Summary
IntraBio's Aqneursa has received approval for a second indication and is now the first treatment globally indicated for rare ataxia, expanding the company's portfolio in rare neurological conditions.
Outcome Details
First treatment globally indicated for rare ataxia; second indication expansion
Importance:6/10
Sentiment:
0.80
rare diseaseneurologicalindication expansionregulatory approval
Read the original article
Published by FiercePharma on September 21, 2026 10:47 AM
